Zobrazeno 1 - 10
of 74
pro vyhledávání: '"KRISZTINA, BOGOS"'
Autor:
Levente Zoltán Bogyó, Klára Török, Zsuzsanna Illés, Anikó Szilvási, Bálint Székely, Anikó Bohács, Orsolya Pipek, Ildikó Madurka, Zsolt Megyesfalvi, Ferenc Rényi-Vámos, Balázs Döme, Krisztina Bogos, Balázs Gieszer, Eszter Bakos
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Donor-specific antibodies (DSAs) are common following lung transplantation (LuTx), yet their role in graft damage is inconclusive. Mean fluorescent intensity (MFI) is the main read-out of DSA diagnostics; however its value is ofte
Externí odkaz:
https://doaj.org/article/e43a89b3b5d84a5a89355b9ff6c33695
Autor:
Zoltán Kiss, Tamás G. Szabó, Csaba Polgár, Zsolt Horváth, Péter Nagy, Ibolya Fábián, Valéria Kovács, György Surján, Zsófia Barcza, István Kenessey, András Wéber, István Wittmann, Gergő Attila Molnár, Eszter Gyöngyösi, Angéla Benedek, Eugenia Karamousouli, Zsolt Abonyi-Tóth, Renáta Bertókné Tamás, Diána Viktória Fürtős, Krisztina Bogos, Judit Moldvay, Gabriella Gálffy, Lilla Tamási, Veronika Müller, Zoárd Tibor Krasznai, Gyula Ostoros, Zsolt Pápai-Székely, Anikó Maráz, Gabriella Branyiczkiné Géczy, Lászlóné Hilbert, Láśzló Tamás Berki, György Rokszin, Zoltán Vokó
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe nationwide HUN-CANCER EPI study examined cancer incidence and mortality rates in Hungary from 2011 to 2019.MethodsUsing data from the National Health Insurance Fund (NHIF) and Hungarian Central Statistical Office (HCSO), our retrospecti
Externí odkaz:
https://doaj.org/article/03adbbbd3d054b19a967d6a6c292c818
Autor:
Gabriella Gálffy, Géza Tamás Szabó, Lilla Tamási, Veronika Müller, Judit Moldvay, Veronika Sárosi, Anna Kerpel-Fronius, Tamás Kardos, Edit Csada, Zsolt Pápai-Székely, Zoltán Szász, Zsolt Király, Gábor Hódi, Zsuzsanna Kovács, Éva Balogh, Krisztina Andrea Kovács, Miklós Darida, Viktória Buga, György Rokszin, Zsolt Abonyi-Tóth, Zoltán Kiss, Zoltán Vokó, Krisztina Bogos
Publikováno v:
Pathology and Oncology Research, Vol 30 (2024)
ObjectiveHungary has repeatedly been shown to have the highest cancer-related mortality and incidence in Europe. Despite lung cancer being the most abundant malignant diagnosis in Hungary, numerous concerns have been raised recently regarding the bia
Externí odkaz:
https://doaj.org/article/9bde8f083408482c872f58d4f50c4120
Autor:
Maximilian J. Hochmair, Mojca Unk, Jelena Spasic, Timur Cerić, Assia Konsoulova, Mircea Dediu, Krisztina Bogos, Alinta Hegmane, Kersti Oselin, Marko Stojiljkovic, Tina Roblek, Marko Jakopovic
Publikováno v:
BMC Proceedings, Vol 18, Iss S3, Pp 1-7 (2024)
Abstract Lung cancer remains the leading cause of cancer-related deaths in Europe, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. NSCLC is a heterogeneous disease encompassing various oncogenic alterations. Among t
Externí odkaz:
https://doaj.org/article/f9f7e046c374460e862662228b2b71f4
Autor:
Anna Kerpel-Fronius, Krisztina Bogos
Publikováno v:
Pathology and Oncology Research, Vol 30 (2024)
Lung cancer, the leading cause of malignancy-related deaths worldwide, demands proactive measures to mitigate its impact. Low-dose computer tomography (LDCT) has emerged as a promising tool for secondary prevention through lung cancer screening (LCS)
Externí odkaz:
https://doaj.org/article/ca0d4e5a46b648f6bb39e2b5e76df861
Autor:
Zoltán Kiss, Gabriella Gálffy, Veronika Müller, Judit Moldvay, Veronika Sárosi, Zsolt Pápai-Székely, Edit Csada, Anna Kerpel-Fronius, Zsolt Király, Zoltán Szász, Gábor Hódi, Zoltán Polányi, Krisztina Kovács, Eugenia Karamousouli, Kata Knollmajer, Tamás G. Szabó, Andrea Berta, Zoltán Vokó, György Rokszin, Zsolt Abonyi-Tóth, Zsófia Barcza, Lilla Tamási, Krisztina Bogos
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectiveThe approval of immunotherapy (I-O) for the treatment of late-stage non-small cell lung cancer (NSCLC) opened new perspectives in improving survival outcomes. However, survival data have not yet been provided from the period of the Covid-19
Externí odkaz:
https://doaj.org/article/af41d80cfb264262bce0e68d6b8a2c77
Autor:
Lörinc Polivka, Istvan Valyi-Nagy, Zoltan Szekanecz, Krisztina Bogos, Hajnalka Vago, Anita Kamondi, Ferenc Fekete, Janos Szlavik, György Surjan, Orsolya Surjan, Peter Nagy, Zsuzsa Schaff, Zoltan Kiss, Cecilia Müller, Miklos Kasler, Veronika Müller
Publikováno v:
Vaccines, Vol 11, Iss 12, p 1786 (2023)
Although the COVID-19 pandemic is profoundly changing, data on the effect of vaccination and duration of protection against infection and severe disease can still be advantageous, especially for patients with COPD, who are more vulnerable to respirat
Externí odkaz:
https://doaj.org/article/26de4f43441e4467ba1085d946cf33d0
Autor:
Zolta´n Kiss, Krisztina Bogos, Lilla Tamási, Gyula Ostoros, Veronika Müller, Nóra Bittner, Veronika Sárosi, Aladár Vastag, Kata Knollmajer, Máté Várnai, Krisztina Kovács, Andrea Berta, István Köveskuti, Eugenia Karamousouli, György Rokszin, Zsolt Abonyi-Tóth, Zsófia Barcza, István Kenessey, András Weber, Péter Nagy, Petra Freyler-Fadgyas, Miklós Szócska, Péter Szegner, Lászlóné Hilbert, Gabriella Branyiczkiné Géczy, György Surján, Judit Moldvay, Zoltán Vokó, Gabriella Gálffy, Zoltán Polányi
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectiveThe Hungarian Undiagnosed Lung Cancer (HULC) study aimed to explore the potential reasons for missed LC (lung cancer) diagnosis by comparing healthcare and socio-economic data among patients with post-mortem diagnosed LC with those who were
Externí odkaz:
https://doaj.org/article/dc1a39dc32514d11b8d8fffbd26a0f45
Autor:
Eszter Bencze, Krisztina Bogos, Andrea Kohánka, László Báthory-Fülöp, Veronika Sárosi, Erzsébet Csernák, Nóra Bittner, Zsombor Melegh, Erika Tóth
Publikováno v:
Pathology and Oncology Research, Vol 28 (2022)
EGFR mutation in non-small cell lung cancer (NSCLC) offers a potential therapeutic target for tyrosine kinase inhibitor (TKI) therapy. The majority of these cases, however eventually develop therapy resistance, mainly by acquiring EGFR T790M mutation
Externí odkaz:
https://doaj.org/article/791ae1e67c614efcaf1a1b0756e5936c
Autor:
Beáta Szeitz, Zsolt Megyesfalvi, Nicole Woldmar, Zsuzsanna Valkó, Anna Schwendenwein, Nándor Bárány, Sándor Paku, Viktória László, Helga Kiss, Edina Bugyik, Christian Lang, Attila Marcell Szász, Luciana Pizzatti, Krisztina Bogos, Mir Alireza Hoda, Konrad Hoetzenecker, György Marko‐Varga, Peter Horvatovich, Balázs Döme, Karin Schelch, Melinda Rezeli
Publikováno v:
Clinical and Translational Medicine, Vol 12, Iss 9, Pp n/a-n/a (2022)
Abstract Background Small‐cell lung cancer (SCLC) molecular subtypes have been primarily characterized based on the expression pattern of the following key transcription regulators: ASCL1 (SCLC‐A), NEUROD1 (SCLC‐N), POU2F3 (SCLC‐P) and YAP1 (
Externí odkaz:
https://doaj.org/article/817dbbeab6fd44cfb710da099fa8d926